Donafenib plus immunotherapy for advanced liver cancer
Treatments studied
Part of Cancer, Digestive system, Immune system & allergy clinical trials.
This study tests a new combination treatment for advanced liver cancer that has stopped responding to earlier therapy. It combines the targeted drug donafenib with immunotherapy and local treatments, which may help control the tumor better than the previous treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 70 years old.
- You must have been diagnosed with liver cancer (hepatocellular carcinoma) that cannot be removed with surgery.
- Your previous cancer treatment (like targeted therapy or immunotherapy, but not donafenib) must have stopped working.
- You must have at least one tumor that can be measured on a scan.
- If you have hepatitis B or C, your viral levels must be well controlled with antiviral medication.
- Your liver function must be within certain limits (Child-Pugh class A or B).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of treatments for liver cancer that cannot be removed with surgery. The treatments include a targeted therapy pill, a procedure that cuts off blood supply to the tumor, and radiation, plus an immunotherapy drug that helps your immune system fight the cancer. This approach aims to shrink tumors and improve outcomes.
This trial is testing a combination of immunotherapy (anti-PD-1/PD-L1) and drugs that block blood vessel growth (anti-angiogenic agents) as a first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a combination of targeted therapy, immunotherapy, and a liver-directed therapy given before surgery to shrink tumors in people with early-stage liver cancer that can be removed. The goal is to make surgery more successful and improve outcomes.
This study looks back at patients who received a combination of donafenib (a targeted pill), immunotherapy (a medicine that helps your immune system fight cancer), and a liver-directed procedure (TACE or HAIC) as their first treatment for liver cancer that can't be surgically removed. The goal is to check how well this combination works and how safe it is.
This study tests a combined treatment for liver cancer that cannot be removed with surgery. It combines a targeted therapy pill (donafenib) with a procedure that delivers chemotherapy directly to the tumor (E-TACE). The goal is to see if this combination helps control the cancer and is safe for patients.
This trial tests a new treatment approach for liver cancer that has spread or can't be removed. It aims to see if the study drug can help control the cancer.
Hear when a new Unresectable Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.